Acadia Finalizes Rare Pediatric Disease Priority Review Voucher Sale For $150M

Acadia Pharmaceuticals Inc. has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million before fees and expenses. Under the terms of a licensing agreement with Neuren Pharmaceuticals Limited, Acadia will share one-third of the net proceeds with Neuren, as outlined when the sale agreement was announced on November 5, 2024.

Acadia plans to use the funds from the PRV to strengthen commercial operations, advance research and development in the central nervous system and rare disease programs, and pursue future business development opportunities.